Zobrazit v EDS

Sex-Specific Differences in Potent P2Y 12 Inhibitor Use in British Cardiovascular Intervention Society Registry STEMI Patients

Uloženo v:
Podrobná bibliografie
Název: Sex-Specific Differences in Potent P2Y 12 Inhibitor Use in British Cardiovascular Intervention Society Registry STEMI Patients
Autoři: Sonya N. Burgess, Ahmad Shoaib, Andrew S.P. Sharp, Peter Ludman, Michelle M. Graham, Gemma A. Figtree, Evangelos Kontopantelis, Muhammad Rashid, Tim Kinnaird, Mamas A. Mamas
Zdroj: Burgess, S, Shoaib, A, Sharp, A, Ludman, P, Graham, M M, Figtree, G A, Kontopantelis, E, Rashid, M & Kinnaird, T 2023, 'Sex-specific differences in potent P2Y12 inhibitor use in British Cardiovascular Intervention Society registry STEMI patients', Circulation: Cardiovascular Interventions, vol. 16, no. 9, e012447. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447
Informace o vydavateli: Ovid Technologies (Wolters Kluwer Health), 2023.
Rok vydání: 2023
Témata: Male, Ticagrelor, ST Elevation Myocardial Infarction/diagnosis, Prasugrel Hydrochloride/adverse effects, 3. Good health, Clopidogrel, Ticagrelor/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Treatment Outcome, Humans, ST Elevation Myocardial Infarction, Female, Registries, Prasugrel Hydrochloride
Popis: BACKGROUND: Sex-based outcome differences for women with ST-segment–elevation myocardial infarction (STEMI) have not been adequately addressed, and the role played by differences in prescription of potent P2Y 12 inhibitors (P-P2Y 12 ) is not well defined. This study explores the hypothesis that disparities in P-P2Y 12 (prasugrel or ticagrelor) use may play a role in outcome disparities for women with STEMI. METHODS: Data from British Cardiovascular Intervention Society national percutaneous coronary intervention database were analyzed, and 168 818 STEMI patients treated with primary percutaneous coronary intervention from 2010 to 2020 were included. RESULTS: Among the included women (43 131; 25.54%) and men (125 687; 74.45%), P-P2Y 12 inhibitors were prescribed less often to women (51.71%) than men (55.18%; P 12 -treated women (5.39%), men treated with clopidogrel (4.60%), and P-P2Y 12 -treated men (3.61%; P 12 prescription was radial access (adjusted odds ratio, 2.368 [95% CI, 2.312–2.425]), used in 67.93% of women and 74.38% of men ( P 12 (adjusted odds ratio, 0.957 [95% CI, 0.935–0.979]) with risk adjustment for baseline characteristics alone, when procedural factors including radial access were included in the model differences were not significant (adjusted odds ratio, 1.015 [95% CI, 0.991–1.039]). CONCLUSIONS: Women were less likely to be prescribed prasugrel or ticagrelor, were less likely to have radial access, and had a higher mortality when being treated for STEMI. Improving rates of P-P2Y 12 use and radial access may decrease outcome disparities for women with STEMI.
Druh dokumentu: Article
Popis souboru: application/vnd.openxmlformats-officedocument.wordprocessingml.document
Jazyk: English
ISSN: 1941-7632
1941-7640
DOI: 10.1161/circinterventions.122.012447
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37725676
https://research.manchester.ac.uk/en/publications/68d56564-fa92-4db0-94a7-ba144ee1d9f4
https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447
https://pure.manchester.ac.uk/ws/files/270578305/TRACKED_P2Y12_july14_MAM_SB.docx
https://research.manchester.ac.uk/en/publications/68d56564-fa92-4db0-94a7-ba144ee1d9f4
https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....9651684beff326ef0dbc5d472b575316
Databáze: OpenAIRE
Popis
Abstrakt:BACKGROUND: Sex-based outcome differences for women with ST-segment–elevation myocardial infarction (STEMI) have not been adequately addressed, and the role played by differences in prescription of potent P2Y 12 inhibitors (P-P2Y 12 ) is not well defined. This study explores the hypothesis that disparities in P-P2Y 12 (prasugrel or ticagrelor) use may play a role in outcome disparities for women with STEMI. METHODS: Data from British Cardiovascular Intervention Society national percutaneous coronary intervention database were analyzed, and 168 818 STEMI patients treated with primary percutaneous coronary intervention from 2010 to 2020 were included. RESULTS: Among the included women (43 131; 25.54%) and men (125 687; 74.45%), P-P2Y 12 inhibitors were prescribed less often to women (51.71%) than men (55.18%; P 12 -treated women (5.39%), men treated with clopidogrel (4.60%), and P-P2Y 12 -treated men (3.61%; P 12 prescription was radial access (adjusted odds ratio, 2.368 [95% CI, 2.312–2.425]), used in 67.93% of women and 74.38% of men ( P 12 (adjusted odds ratio, 0.957 [95% CI, 0.935–0.979]) with risk adjustment for baseline characteristics alone, when procedural factors including radial access were included in the model differences were not significant (adjusted odds ratio, 1.015 [95% CI, 0.991–1.039]). CONCLUSIONS: Women were less likely to be prescribed prasugrel or ticagrelor, were less likely to have radial access, and had a higher mortality when being treated for STEMI. Improving rates of P-P2Y 12 use and radial access may decrease outcome disparities for women with STEMI.
ISSN:19417632
19417640
DOI:10.1161/circinterventions.122.012447